<DOC>
	<DOC>NCT01621269</DOC>
	<brief_summary>Study to evaluate efficacy of fingolimod in patients with neutralizing antibodies over 12 months</brief_summary>
	<brief_title>ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Male or female subjects aged 1865 years Subjects with relapsing remitting MS defined by 2010 revised McDonald criteria Patients with Expanded Disability Status Scale (EDSS) score of 06.5 Interferonbeta (IFNβ) treatment for at least 18 months. Positive IFNNAb titer at screening or within 6 months prior to screening Patients with disease activity despite treatment with IFNß measured by gadoliniumenhancing lesions on T1weighted images on MRI using a tripledose gadolinium protocol and/or new or newly enlarging T2 lesions (T2 lesions: compared to a reference MRI performed within the last 18 months) patients with previous or current disease of immune system active infections cardiovascular risk patients Patients unable to undergo MRI scans, including claustrophobia or history of hypersensitivity to gadoliniumDTPA Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>Fingolimod</keyword>
	<keyword>Gilenya</keyword>
	<keyword>Neutralizing Antibodies</keyword>
	<keyword>NAb</keyword>
</DOC>